Yoon‐koo Kang
#142,184
Most Influential Person Now
Yoon‐koo Kang's AcademicInfluence.com Rankings
Yoon‐koo Kangphilosophy Degrees
Philosophy
#7464
World Rank
#10684
Historical Rank
Logic
#4511
World Rank
#5820
Historical Rank
Download Badge
Physics Philosophy
Yoon‐koo Kang's Degrees
- Bachelors Physics Seoul National University
- Masters Physics Seoul National University
- PhD Physics Seoul National University
Why Is Yoon‐koo Kang Influential?
(Suggest an Edit or Addition)Yoon‐koo Kang's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010) (5682)
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (2009) (4720)
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (2017) (2764)
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1426)
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (1006)
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (969)
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. (2013) (750)
- Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* (1997) (691)
- Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. (2013) (652)
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors (2017) (575)
- Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (2013) (522)
- Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. (2014) (513)
- SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. (2015) (481)
- Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. (2015) (478)
- Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. (2011) (477)
- Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. (2012) (452)
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) (433)
- Management of gastric cancer in Asia: resource-stratified guidelines. (2013) (404)
- A phase III randomized study of 5‐fluorouracil and cisplatin versus 5‐fluorouracil, doxorubicin, and mitomycin C versus 5‐fluorouracil alone in the treatment of advanced gastric cancer (1993) (362)
- The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines (2015) (331)
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. (2017) (325)
- Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours (2020) (290)
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. (2018) (261)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. (2012) (238)
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma (2011) (200)
- Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients. (2007) (193)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2019) (187)
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer (2010) (187)
- Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. (2016) (167)
- Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors (2004) (163)
- Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. (2017) (159)
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study (2019) (158)
- Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. (2013) (156)
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. (2017) (156)
- Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients (2006) (151)
- Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) (2007) (149)
- Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. (2019) (146)
- Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor (2016) (142)
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. (2020) (141)
- Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. (2013) (131)
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022) (130)
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data (2019) (129)
- Clinicopathologic analysis of ocular adnexal lymphomas: Extranodal marginal zone b‐cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients (2003) (126)
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021) (122)
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. (2015) (113)
- Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. (2002) (112)
- Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients? (2011) (105)
- Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. (2010) (104)
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer (2014) (100)
- Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. (2017) (100)
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022) (96)
- Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. (2002) (96)
- Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy (2007) (93)
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. (2018) (92)
- 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY (2012) (92)
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. (2020) (92)
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. (2015) (92)
- Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib (2015) (90)
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. (2022) (89)
- Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. (2010) (89)
- Leptomeningeal Carcinomatosis in Gastric Cancer (2004) (88)
- Extrapulmonary small cell carcinoma: Single center experience with 61 patients (2007) (85)
- A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). (2016) (84)
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer (2011) (84)
- Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). (2013) (82)
- A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. (2016) (82)
- Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib (2011) (82)
- Management of advanced gastric cancer (2012) (81)
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (81)
- Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. (2017) (76)
- Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? (2012) (75)
- Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs) (2008) (73)
- Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. (2012) (73)
- Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients (2016) (71)
- Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma (2016) (71)
- Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer (2008) (71)
- Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. (2013) (70)
- Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea (2007) (69)
- Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck (2008) (69)
- A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy (2008) (68)
- Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). (2016) (68)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. (2016) (66)
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach (2017) (66)
- Gastrointestinal stromal tumours (2021) (65)
- Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. (2015) (64)
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) (2018) (64)
- Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors (2020) (63)
- A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models (2011) (63)
- Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea (2012) (61)
- PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer (2021) (60)
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma. (2019) (59)
- Clinical impact of EUS-guided Trucut biopsy results on decision making for patients with gastric subepithelial tumors ≥ 2 cm in diameter. (2011) (59)
- Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). (2021) (56)
- Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis (2009) (55)
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer (2017) (55)
- Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review (2017) (55)
- Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer (2012) (54)
- Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (2004) (53)
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial (2019) (53)
- Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer (2010) (53)
- Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus (2016) (52)
- Hand‐Foot Syndrome in Patients Treated With Capecitabine‐Containing Combination Chemotherapy (2004) (52)
- MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. (2020) (51)
- Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial (2021) (50)
- Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. (2016) (50)
- Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function (2011) (49)
- Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial (2016) (49)
- A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma (2013) (48)
- Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study (2011) (48)
- Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. (2019) (47)
- Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. (2007) (46)
- A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) (2018) (46)
- Prognostic significance of neuroendocrine components in gastric carcinomas. (2014) (46)
- Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study (2013) (45)
- Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. (2018) (45)
- Quality of life in the trastuzumab for gastric cancer trial. (2014) (45)
- Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC) (2012) (43)
- The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. (2003) (42)
- Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. (2013) (42)
- A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors (2018) (42)
- Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). (2015) (42)
- Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. (2015) (42)
- Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. (2012) (42)
- The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses (2014) (41)
- Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer (2019) (41)
- EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. (2014) (40)
- Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study. (2016) (40)
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab (2021) (40)
- The Effects of Surgical Cytoreduction Prior to Imatinib Therapy on the Prognosis of Patients with Advanced GIST (2013) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens (2019) (39)
- Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. (2007) (39)
- Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer (2011) (39)
- Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. (2006) (38)
- Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases. (2003) (36)
- Clinical Reversal of Multidrug Resistance (1996) (35)
- Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY) (2019) (34)
- Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial (2019) (34)
- Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis (2016) (33)
- Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. (2021) (33)
- Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients (2017) (33)
- Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study (2012) (32)
- Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor (2014) (32)
- Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors (2015) (32)
- The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. (2015) (32)
- Primary central nervous system marginal zone B-cell lymphoma of the Basal Ganglia mimicking low-grade glioma: a case report and review of the literature. (2008) (32)
- A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer (2008) (31)
- Primary Malignant Lymphoma of the Breast: Clinicopathological Study of Nine Cases (2004) (31)
- Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane (2008) (31)
- Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer (2008) (31)
- Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. (2012) (31)
- Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB). (2013) (31)
- Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST (2008) (31)
- Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study (2021) (31)
- Response to Imatinib in KIT- and PDGFRA-Wild Type Gastrointestinal Stromal Associated with Neurofibromatosis Type 1 (2006) (31)
- Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor (2016) (30)
- Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer (2019) (30)
- A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial. (2015) (30)
- Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer (2015) (30)
- Postoperative Nodal Status and Diffuse-type Histology Are Independent Prognostic Factors in Resectable Advanced Gastric Carcinomas After Preoperative Chemotherapy (2013) (29)
- Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. (2012) (29)
- A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor (2009) (29)
- Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab (2021) (28)
- A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer (2013) (28)
- Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study (2007) (28)
- Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution (2015) (28)
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. (2021) (28)
- Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer (2011) (28)
- S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. (2020) (28)
- INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results. (2015) (28)
- Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor (2005) (28)
- Serum CA 19‐9 as a prognostic factor in patients with metastatic gastric cancer (2013) (27)
- The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients (2009) (26)
- Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm (2017) (26)
- Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial (2005) (26)
- Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. (2016) (26)
- Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma (2012) (26)
- Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 (2020) (25)
- Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. (2013) (25)
- Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial (2016) (25)
- Significantly Better Prognosis for Patients with Primary Plasma Cell Leukemia than for Patients with Secondary Plasma Cell Leukemia (2007) (25)
- Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. (2008) (25)
- MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy. (2016) (25)
- Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation (2013) (25)
- Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors. (2014) (25)
- Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients (2012) (24)
- Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. (2006) (24)
- Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status (2012) (24)
- Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression (2015) (24)
- Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial) (2020) (24)
- A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC) (2001) (24)
- Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC). (2015) (24)
- Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D). (2018) (23)
- A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer (2017) (23)
- Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer (2014) (23)
- Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer (2012) (23)
- Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer (2010) (23)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. (2020) (23)
- Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma (2014) (23)
- Polymerase chain reaction‐based diagnosis of bone marrow involvement in 170 cases of non‐Hodgkin lymphoma (2002) (23)
- Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). (2019) (22)
- Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors (2013) (22)
- Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib ( GRID ) : an international , multicentre , randomised , placebo-controlled , phase 3 trial (2013) (22)
- Fine needle aspiration cytology of CD56‐positive natural killer/T‐cell lymphoma of soft tissue (2002) (22)
- Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) (2018) (21)
- Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma (2016) (21)
- Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer (2002) (21)
- Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) : Subgroup analysis of outcomes based on pretreatment characteristics (2013) (21)
- Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101) (2013) (21)
- Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers (2016) (20)
- Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery (2011) (20)
- Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia (2019) (20)
- Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer (2016) (20)
- A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer (2007) (20)
- A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours (2018) (20)
- KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. (2017) (20)
- Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure (2012) (19)
- Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. (2009) (19)
- Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). (2019) (19)
- FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). (2021) (19)
- Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program (2016) (18)
- Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. (2011) (18)
- INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)--A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. (2015) (18)
- Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability (2011) (18)
- Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum. (2005) (18)
- ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer (2009) (18)
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. (2022) (18)
- Unmet needs of non‐Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health‐related quality of life (2017) (17)
- A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity (2012) (17)
- A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer (2007) (17)
- Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer (2020) (17)
- A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel (2013) (17)
- FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. (2015) (16)
- Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea (2007) (16)
- Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients (2021) (16)
- Predictors of Recurrence After Resection of Small Gastric Gastrointestinal Stromal Tumors of 5 cm or Less (2012) (16)
- Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (2020) (16)
- Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors (2018) (16)
- LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. (2017) (16)
- Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients (2004) (16)
- A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer (2017) (15)
- Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. (2005) (15)
- P-0111PERTUZUMAB, TRASTUZUMAB AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER: AN INTERNATIONAL PHASE III STUDY (JACOB) (2013) (15)
- Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation. (2015) (14)
- A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer (2007) (14)
- Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. (2021) (14)
- A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. (2012) (14)
- Intraoperatively Assessed Macroscopic Serosal Changes in Patients with Curatively Resected Advanced Gastric Cancer: Clinical Implications for Prognosis and Peritoneal Recurrence (2015) (14)
- A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. (2014) (14)
- Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications (2015) (13)
- Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis (2017) (13)
- Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). (2018) (13)
- Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study (2017) (13)
- Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer (2012) (13)
- Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours (2019) (13)
- Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer (2010) (13)
- Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients (2013) (12)
- Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). (2018) (12)
- Current Status and Challenges of Cancer Clinical Trials in Korea (2015) (12)
- Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial (2022) (12)
- Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors (2020) (12)
- Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST). (2013) (12)
- Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer (2015) (12)
- A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors (2018) (12)
- Perioperative FLOT: new standard for gastric cancer? (2019) (12)
- Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies (2020) (12)
- A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. (2020) (11)
- The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis (2017) (11)
- Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer (2016) (11)
- Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. (2020) (11)
- Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis (2017) (11)
- Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy. (2016) (11)
- Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. (2004) (11)
- Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST). (2016) (10)
- Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. (2022) (10)
- A phase I trial to determine the maximum tolerated dose and evaluate the safety and pharmacokinetics (PK) of docetaxel-PNP, polymeric nanoparticle formulation of docetaxel, in subjects with advanced solid malignancies. (2012) (10)
- Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study. (2016) (10)
- Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients (2012) (10)
- Oral Doxifluridine Plus Leucovorin in Metastatic Colorectal Cancer: Randomized Phase II Trial With Intravenous 5-Fluorouracil Plus Leucovorin (2003) (10)
- Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. (2019) (10)
- A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas. (2017) (10)
- Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial (2018) (9)
- A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Prospective, Multicenter Trial of the Korean Cancer Study Group (2014) (9)
- A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia (2006) (9)
- Predictive biomarkers for the efficacy of nivolumab as ≥ third-line therapy in patients with advanced gastric cancer (AGC): From a subset analysis of ATTRACTION-2 phase III trial. (2019) (9)
- Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice (2017) (9)
- Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib (2016) (9)
- Phase II Study of Gemcitabine, UFT and Leucovorin in Patients with Advanced Pancreatic Cancer (2002) (9)
- LBA-06INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results (2015) (9)
- Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience (2019) (9)
- A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY). (2015) (9)
- Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC). (2015) (8)
- Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study (2017) (8)
- Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis (2008) (8)
- An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID). (2015) (8)
- Clinical value of cyclooxygenase-2 expression in human breast carcinoma. (2004) (8)
- Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance (2014) (8)
- Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 (2018) (8)
- Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). (2016) (8)
- O-0021PERTUZUMAB PHARMACOKINETICS AND SAFETY IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED GASTRIC CANCER (AGC) (2013) (8)
- PDGFRα Gene Mutation and Protein Expression in Gastrointestinal Stromal Tumors (2008) (8)
- 3501 ORAL Capecitabine/cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients (pts) with advanced gastric cancer (AGC): a randomised phase III trial (2007) (8)
- Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors of the stomach: report of three cases. (2006) (8)
- Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC). (2018) (8)
- Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC). (2016) (8)
- INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib (2022) (8)
- Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study. (2019) (8)
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (7)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial. (2018) (7)
- Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. (2005) (7)
- Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. (2007) (7)
- Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. (2022) (7)
- Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study. (2013) (7)
- Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2021) (7)
- Prognostic impact of extranodal extension in stage 1B gastric carcinomas. (2018) (7)
- 4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis (2014) (7)
- Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence. (2012) (7)
- Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2). (2019) (7)
- Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB–IV gastric cancer (2015) (6)
- JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma. (2014) (6)
- Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update (2012) (6)
- Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 (2020) (6)
- Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study (2021) (6)
- Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel (2020) (6)
- Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial (2011) (6)
- Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial (2022) (6)
- Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors. (2020) (6)
- Update of AMC 0101 study: A phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322). (2012) (6)
- The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene. (2020) (6)
- First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors. (2016) (6)
- The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST. (2013) (5)
- 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors (2020) (5)
- Diagnosis and Treatment of Gastrointestinal Stromal Tumor (2013) (5)
- Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer (2019) (5)
- Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib (2015) (5)
- INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG). (2013) (5)
- Continued Sunitinib Treatment After Progressive Disease (PD) in a Worldwide Treatment-Use Trial of Patients (PTS) With Gastrointestinal Stromal Tumor (GIST) (2012) (5)
- A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors. (2014) (5)
- EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial. (2016) (5)
- Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. (2014) (5)
- A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA) (2015) (5)
- A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study. (2017) (4)
- Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor (2019) (4)
- Primary Non-Hodgkin's Lymphoma of Bone : A Single Institution Experience (2002) (4)
- Natural killer cells in human peripheral blood and primary cutaneous natural killer cell lymphomas may express cutaneous lymphocyte antigen. (2003) (4)
- Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). (2021) (4)
- Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST. (2013) (4)
- 2364 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib trial (2015) (4)
- Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting (2020) (4)
- Perioperative treatments for resectable gastric cancer (2015) (4)
- Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 (2015) (4)
- Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts. (2012) (4)
- Both-sided intra-atrial intracardiac metastases as the initial presentation of testicular seminoma. (2007) (4)
- Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC). (2021) (4)
- Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab (2021) (4)
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3). (2017) (4)
- Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors — 8 cases: A case report (2019) (3)
- Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2. (2019) (3)
- Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours (2019) (3)
- Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC). (2016) (3)
- Infarction and Perforation of the Small Intestine due to Tumor Emboli from Disseminated Rectal Cancer. (2008) (3)
- Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study (2021) (3)
- 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC) (2020) (3)
- 3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer (2007) (3)
- Palliative treatment of malignant gastric outlet obstructions with a large-diameter metallic stent: prospective preliminary study. (2010) (3)
- Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study (2023) (3)
- Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy (2019) (3)
- An update of adjuvant treatments for localized advanced gastric cancer (2012) (3)
- Update of AMC 0201 study: A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (NCT00296335). (2011) (3)
- Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis (2021) (3)
- Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1–positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial. (2020) (3)
- Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. (2020) (3)
- Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials (2022) (3)
- Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors (2017) (3)
- A phase I/II study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors (phase I) and gastric cancer (phase II). (2014) (3)
- Subclassification of diffuse large B-cell lymphomas according to the REAL classification: Distinction of immunoblastic and non-immunoblastic subtypes (2003) (3)
- Capecitabine in the treatment of advanced gastric cancer. (2008) (3)
- Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC). (2012) (2)
- Abstract 2874: A prospective study of a repeat endoscopic biopsy to identify HER2-positive tumors following an initial HER2-negative endoscopic biopsy in unresectable or metastatic gastric cancer patients: GASTHER1 study (2014) (2)
- Immunotherapy for advanced gastric cancer. (2018) (2)
- Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer) (2020) (2)
- Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report (2011) (2)
- Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer (2019) (2)
- Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer. (2014) (2)
- Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer (2009) (2)
- Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success (2020) (2)
- A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction (2011) (2)
- Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial. (2014) (2)
- Self-Rated Pain Assessment by Patients With HER2-Positive Advanced Gastric/GEJ Cancer Treated With 5-FU/Capecitabine and Cisplatin With or Without Trastuzumab: Exploratory QOL Analysis From the Phase III ToGA Study (2011) (2)
- Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab (2022) (2)
- Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis (2019) (2)
- Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST). (2014) (2)
- Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab (2021) (2)
- A phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine and cisplatin (DXP) in patients with advanced unresectable or intra-abdominal metastatic gastric cancer (2007) (2)
- Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. (2017) (2)
- Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. (2018) (2)
- Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients. (2006) (2)
- Abstract CT058: Phase I study of LY2874455, a fibroblast growth factor (FGF) receptor inhibitor, in patients with advanced cancer (2016) (2)
- Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses. (2018) (2)
- 7511 POSTER Safety and efficacy results of sunitinib from a worldwide treatment- use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy (2007) (2)
- PLS-3SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE PHASE III TRIAL (GRID) OF REGORAFENIB IN PRETREATED METASTATIC GIST (2013) (2)
- Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer. (2021) (2)
- First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. (2022) (2)
- Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. (2012) (2)
- A multinational phase II clinical trial of neoadjuvant imatinib for large gastrointestinal stromal tumor of the stomach. (2016) (2)
- Clinico-hematologic Findings of Leukemic Bone Marrow Involvement in Korean Patients with Non-Hodgkin Lymphoma (2011) (2)
- Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses (2019) (2)
- Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE. (2023) (2)
- Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG). (2016) (2)
- Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib (2022) (2)
- A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM). (2015) (1)
- Phase II Study of Concurrent Chemotherapy with Etoposide and Cisplatin (EP) and Radiation Therapy for Unresectable Stage III Non-small Cell Lung Cancer (1997) (1)
- Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study (2022) (1)
- Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC). (2018) (1)
- An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors. (2020) (1)
- Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial. (2014) (1)
- A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours (2019) (1)
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (1)
- Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST). (2022) (1)
- P-0303 Safety and Tolerability data from A Phase II Study of Auy922 Compared with Chemotherapy in Patients with Advanced Gastric Cancer (2012) (1)
- A Multicenter, Phase III Clinical Trial of Leucogreen®(G-CSF) for Chemotherapy-Induced Neutropenia in Solid Tumors (2003) (1)
- CDK 4 Down-Regulation Induced by Paclitaxel Is Associated with G 1 Arrest in Gastric Cancer Cells 1 (2005) (1)
- 2308 Association between CYP2A6 polymorphisms and treatment outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer (2015) (1)
- Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial (2015) (1)
- The role of surgical cytoreduction before imatinib therapy in patients with advanced GIST. (2012) (1)
- Rectal gastrointestinal stromal tumor: clinical features, endoscopic findings and prognosis. (2014) (1)
- O-016Exploratory analysis of tumor growth rate in patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib in the GRID phase 3 trial (2015) (1)
- Gastric Cancer Management — East vs. West? (2016) (1)
- Nilotinib vs imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours: randomised phase 3 trial results and subgroup analysis of molecular subtypes (2015) (1)
- Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study. (2015) (1)
- 0029 The effects of preoperative 18F-FDG-PET/CT in breast cancer patients in comparison with conventional imaging study (2009) (1)
- Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2) (2019) (1)
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023) (1)
- Complete remission of high grade gastric MALT lymphoma after Helicobacter pylori eradication: a case report (2004) (1)
- Fractionated stereotactic radiosurgery for primary hepatocellular carcinoma (2008) (1)
- A Case of Chylous Ascites Associated with Non-Hodgkin's Lymphoma and Liver Cirrhosis (2002) (1)
- A prospective study of repeat endoscopic biopsy to identify HER2-positive tumors following an initial HER2-negative biopsy in unresectable or metastatic gastric cancer: Gasther-1. (2014) (1)
- 64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047 (2016) (1)
- Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function (2011) (1)
- Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis (2019) (1)
- O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study (2020) (1)
- A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group. (2013) (1)
- Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC). (2020) (1)
- Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors (2021) (1)
- A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer (2011) (1)
- Safety and feasibility of adjuvant chemotherapy with S-1 in Korean patients with curatively resected advanced gastric cancer. (2012) (1)
- Primary gastrointestinal diffuse large B-cell lymphoma: A clinical analysis of 76 patients with special application of International Prognostic Index for survival (2007) (1)
- Clinical significance of MET amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum (FP) combination chemotherapy. (2016) (1)
- A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer. (2013) (1)
- Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer (2007) (0)
- Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA) (2019) (0)
- Significant Symptom Relief with Hepatic Artery Embolization in a VIPoma with Liver Metastases (2014) (0)
- Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). (2023) (0)
- Analysis of Bone Marrow Micrometastasis Using RT-PCR in Patients with Small Cell Lung Carcinoma (1999) (0)
- Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success (2020) (0)
- Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis. (2015) (0)
- Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer. (2023) (0)
- Abstract 1269: P-glycoprotein expression in refractory gastrointestinal stromal tumors and its implication in the efficacy of paclitaxel as a salvage treatment (2019) (0)
- Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression. (2015) (0)
- Abstract CT120: Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer (2015) (0)
- Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang. (2007) (0)
- A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors. (2015) (0)
- Tu1483 - Hepatic Safety and Biomarker Assessments in Sorafenibexperienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study (2018) (0)
- A Clinical Study on the Cardiac Toxicity of Adriamycin (1991) (0)
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. (2023) (0)
- Abstract B211: Comparison of detection of FGFR2 amplification by quantitative real-time-PCR (qPCR) and fluorescent in situ hybridization (FISH) in gastric cancer. (2013) (0)
- 500PD NEW DIAGNOSTIC TECHNIQUES IN EARLY DIAGNOSIS OF MELANOMA IN SITU (2006) (0)
- Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE) (2022) (0)
- A randomized phase III study of adjuvant capecitabine vs observation in curatively resected stage IB (by AJCC 6th edition) gastric cancer (CATALYSIS; KCSG ST14-05). (2015) (0)
- A Case of Non-Hodgkin's Lymphoma Associated with Hepatocellular Carcinoma. (1997) (0)
- A phase II study of erlotinib as a first-line therapy for non-small-cell lung cancer patients with favorable clinical predictors and/or molecular predictors (2007) (0)
- Efficacy and Safety Study of Docetaxel as Salvage C hem otherapy in M etastatic G astric C ancer Failing Fluoropyrim idine and Platinum C om bination C hem otherapy (2009) (0)
- Neoadjuvant Treatment for Gastric Cancer (2019) (0)
- SUVmax of F-18 FDG-PET/CT in advanced gastric cancer with tubular adenocarcinoma: Correlation with pathologic findings including immunohistochemical staining. (2010) (0)
- Diagnostic accuracy of CT-staging of advanced gastric cancer following neoadjuvant chemotherapy. (2020) (0)
- Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum chemotherapy for metastatic, recurrent, or locally advanced unresectable gastric cancer. (2023) (0)
- Abstract 1058: Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: Analyses of clinopathological characteristics related with success (2019) (0)
- Pro spective Phase II Study of Preo perative Ch em or adiatio n w ith C apecitabine in L oc ally A dvanced R ectal C ancer (2004) (0)
- Prognostic role of mismatch repair deficiency (MMR-D) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy for metastatic and locally advanced unresectable gastric cancers (GCs). (2020) (0)
- Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours (2020) (0)
- Abstract 3986: Digital droplet PCR measurement for plasmaHER2amplification in patients with AGC (2019) (0)
- Predictive role of mismatch repair deficiency (MMR-D) in patients receiving first-line fluoropyrimidine and platinum (F-P) doublet chemotherapy for metastatic and locally advanced unresectable gastric cancers (GC). (2020) (0)
- 6563 Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer (2009) (0)
- Perioperative treatments for resectable gastric (2015) (0)
- A Case of Primary Mediastinal Germ Cell Tumor Associated with Klinefelter's Syndrome (1996) (0)
- Gastrointestinal stromal tumor with a new concept and promising treatment (2002) (0)
- Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus. (2015) (0)
- Abstract A13: Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors (2015) (0)
- A Case of Cushing's Syndrome Associated with Ectopic Corticotropin Production in Patient with Small-Cell Lung Cancer (1995) (0)
- A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report. (2023) (0)
- Phase I/II study of a combination of capecitabine, cisplatin, and intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis. (2015) (0)
- A case of Non-Hodgkin's lymphoma following Hodgkin's lymphoma (2006) (0)
- A case of adriamycin-induced cardiomyopathy confirmed by endomyocar- dial biopsy. (1991) (0)
- Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial (2022) (0)
- A Case of Erythrodermic Mycosis Fungoides Treated with Gemcitabine (2010) (0)
- Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression (2015) (0)
- Prognostic significance of p53 protein overexpression in localized gastrointestinal stromal tumors of the small intestine. (2013) (0)
- Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH) (2023) (0)
- Phase II study of irinotecan in combination with capecitabine as a first‐line chemotherapy in Asian patients with inoperable hepatocellular carcinoma (2009) (0)
- Phase I/II study of combination chemotherapy with S-1 and cisplatin every 3 week schedule in patients with metastatic or recurrent gastric cancer (2007) (0)
- Erratum to: Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation (2012) (0)
- Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552]. (2019) (0)
- Abstract A118: Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma (2019) (0)
- Predictive value of KRAS mutation and skin rash in Korean colorectal cancer patients treated with cetuximab (2008) (0)
- Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients (2016) (0)
- MO20-2 Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer (2021) (0)
- Real-Life Data of Sorafenib in Unresectable Hepatocellular Carcinoma (2014) (0)
- Cyberknife stereotactic radiosurgery in patients with primary hepatocellular carcinoma (2007) (0)
- Kaposi Sarcoma Developed During Corticosteroid Therapy in Patient with Idiopathic Thrombocytopenic Purpura (2002) (0)
- Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial (2016) (0)
- Erratum to “Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells” (2001) (0)
- O2-14-1Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 Study (2017) (0)
- Three Cases Treated with High-dose Cytarabine and Etoposide followed by Autologous Stem Cell Transplantation for Relapsed Primary CNS Lymphoma (2005) (0)
- BEAC or BEAM Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma Patients: Comparative Analysis on Efficacy and Toxicity. (2005) (0)
- Prognostic significance of preoperative serum tumor markers in the patients with curatively resected advanced gastric cancers (2009) (0)
- Abstract 2187: Circulating tumor DNA (ctDNA) gene sequencing results from prospective screening of patients with newly diagnosed metastatic gastric and gastroesophageal adenocarcinoma (GEA) for the bemarituzumab FIGHT randomized trial using a plasma NGS assay (2021) (0)
- Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer (2022) (0)
- Corrigendum to 'Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer', [Eur J Canc 51 (2015) 482-488]. (2021) (0)
- Reply to D.-C. Mo et al. (2021) (0)
- [Prediction of malignant potential of gastrointestinal stromal tumors]. (2004) (0)
- Capedtabine in Advanced Gastric or Oesophagogastric Cancer (2012) (0)
- Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial (2022) (0)
- Efficacy and safety of Leukoup$^{\circledR}$ (Filgrastim, rhG-CSF) for chemotherapy induced neutropenia in solid tumors : A randomized, multicenter, phase III comparison with Grasin$^{\circledR}$ (2005) (0)
- Incidence and risk factors of thromboembolism (TE) in advanced gastric cancer (AGC) receiving chemotherapy: A prospective observational study (NCT01047618). (2014) (0)
- Mucosa-Associated Lymphoid Tissue Lymphoma Following Kidney Transplantation (2002) (0)
- A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA). (2014) (0)
- Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions. (2022) (0)
- IS3. Gastric Cancer (2012) (0)
- Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib. (2018) (0)
- New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy (2021) (0)
- Identification of Risk Factors of Relapse after Curative Surgical Resection in Stage I Gastric Cancer (2012) (0)
- Bevacizumab in Combination With Chemotherapy as First-LineTherapyinAdvancedGastricCancer:ABiomarker EvaluationFromtheAVAGASTRandomizedPhaseIIITrial (2012) (0)
- P30 Tissue microarray-based studies of patients with lymph node-negative breast carcinoma show that HER-2/neu overexpression is an important predictive marker of poor prognosis (2007) (0)
- The Effect of Intensified Induction Using Vanderbilt Regimen in Patients with an Intermediate Grade Non-Hodgkin's Lymphoma Having 2 or 3 Adverse Factors on the Age-adjusted International Prognostic Index. (2002) (0)
- DNA mismatch repair deficiency and outcomes of patients with resectable locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery and postoperative S-1: A sub-analysis of the phase 3 PRODIGY trial. (2023) (0)
- Serial monitoring of imatinib pharmacokinetics (PK) in perioperative imatinib treatment in patients (pts) with gastrointestinal stromal tumors (GISTs): Results from the multinational phase II trial. (2017) (0)
- A case of primary pulmonary NK-cell lymphoma (2005) (0)
- A Phase I Dose-Finding Study of Vorinostat (V) Combined with Capecitabine (X) and Cisplatin (P) as First-Line Therapy in Patients with advanced Gastric Cancer (2012) (0)
- Intensified induction followed by high-dose therapy with autologous peripheral blood stem cell support in poor-prognosis aggressive non-Hodgkin's lymphoma: results of a pilot study. (2002) (0)
- A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer. (2013) (0)
- A case of primary effusion lymphoma in a patient with alcoholic liver cirrhosis (2008) (0)
- 일 임상 이동식 Prognostic Factors and Clinicopathologic Features after Resection of Small Hepatocellular Carcinoma ( ≤ 2 (2009) (0)
- 807 IMPACT OF LUNG AND LYMPH NODE METASTASIS ON EFFICACY AND SAFETY FOLLOWING TREATMENT WITH SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA FROM THE ASIA-PACIFIC REGION (2009) (0)
- Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors. (2012) (0)
- E fficacy and Safety Study o f D oc etaxel as Salvage C hem ot herapy in M etastatic G astric C ancer Failing Fluo ro py rim idine and Platinum C omb inatio n C hem ot herapy (2005) (0)
- Abstract 4531: SWATH-MS profiling identifies prognostic factors for progression-free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Gr (2019) (0)
- Three Cases of Interstitial Pneumonitis Developed after Anticancer Chemotherapy Containing Cyclophosphamide. (1997) (0)
- INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) (2023) (0)
- A Phase II study of IMEP for Prevously Untreated Stage I/II Extranodal NK/T Cell Lymphoma , Nasal Type: Interim Analysis of KCSG-LY04-03 Trial (초) (2008) (0)
- Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program. (2015) (0)
- 402 Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer (2021) (0)
- Primary Malignant Lymphoma of the Breast - Clinicopathological study of 9 cases - (2002) (0)
- A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours (2018) (0)
- A nthracycline and T axane Salvage T reatm ent of M etastatic Breast C ancer: Retrospective A naly sis of 124 Patients (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Yoon‐koo Kang?
Yoon‐koo Kang is affiliated with the following schools:
